Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States. Its portfolio consists of royalties on approximately 35 marketed therapies and 14 development-stage product candidates that address various therapeutic areas, such as rare disease, cancer, neuroscience, infectious disease, hematology, and diabetes. The company was founded in 1996 and is based in New York, New York.

Royalty Pharma plc

Royalty Pharma ( ($RPRX) ) has provided an announcement. On June 4, 2026, Royalty Pharma held its 2026 Annual General Meeting of Shareholders, wher...

Royalty Pharma Shareholders Back Board, Pay and Flexibility

Royalty Pharma ( ($RPRX) ) has shared an announcement. On May 22, 2026, Royalty Pharma plc entered into a new $1.8 billion unsecured revolving cred...

Royalty Pharma Secures New $1.8 Billion Credit Facility

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Amneal Pharmaceuticals (AMRX), Immunovant (IMVT) and...

Market Cap	$16.52B	P/E Ratio	10.49
52W High	$56.50	52W Low	$34.08
Div Yield	94.0%	Payout Ratio	44.3%
EPS Growth 3Y	161.6%	52W Position	84.2%
Overall Score	76	Value Score	100
Quality Score	55	Technical Score	75

EPS Current Est	$5.05	EPS Next Est	$5.51
EPS Growth Est	+9.1%	DPS Growth 3Y	0.0%

	A	B	C	D
1	Symbol	Price	Change	Volume
2	RPRX	$52.96	-1.38%	8.61M
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	RPRX	$52.96	-1.4%	8.61M
3
4
5
6

RPRX

RPRX

Key Metrics Overview

Growth Analysis

Revenue (5Y)

EBITDA (5Y)

Get Royalty Pharma plc Data in Excel

Get Royalty Pharma plc Data in Excel